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The Nature And Applications Of 
TRYPTIC ENZYMES 
IN VETERINARY PRACTICE 
Earl F. Huffman, D.V.M. 
ENZYMES, or ferments as they were known in earlier times, have been 
used in medicine for centuries. From the 
time of Pasteur interest in enzymes has 
increased till, at the present date, we have 
active research groups devoting much 
time and money to the study of the nature 
and applied uses of a great variety of 
enzymes. 
. Most chemical reactions which occur in 
living cells are accelerated by enzymes. 
Essentially, enzymes are biological cata-
lysts and are protein in nature. Most en-
zymes are water soluble. As they exist 
within the mammalian body, enzymes may 
be surrounded by other proteins. They are 
thus completely liberated only when this 
protein is dissolved since they cannot dif-
fuse through it. Enzymes are amphoteric 
in character and, as such, act as electro-
lytes in various solutions (1). 
Proteolytic enzymes, at the present time, 
command the greatest interest in the field 
of medicine and surgery. The common 
sources of these products are from certain 
streptococci (streptokinase), the pancreas 
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glands of domestic animals (trypsin), or 
from the vegetable kingdom as in the case 
of papain. 
Of the three major types papain is per-
haps the most proteolytic of the group (1). 
However, it strongly attacks viable mam-
malian proteins and is difficult to control 
unless very closely supervised in its ap-
plication. For that reason papain has be-
come restricted in routine use in medicine, 
The mammalian enzymes such as tryp-
sin and chymotrypsin have been intensely 
tested as debriding agents in wound treat-
ments and found to be safe for routine use 
(2, 3, 4, 5). One of the first crude uses of 
trypsin was in the application of maggots 
to gangrenous wounds during World War 
1. It has since been found that the blow 
fly maggots elaborated a tryptic substance 
which accomplished an efficient digestion 
of necrotic material in wounds, especially 
infected type injuries. 
Recent studies (2, 3, 6, 7) in the field 
of medicine and veterinary medicine have 
indicated their value in conditions which 
would require radical surgical procedures 
to effect debridement of dirty wounds be-
fore healing could be accomplished. Tryp-
sin has been used very effectively in the 
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treatment of topical injuries and has also 
been suc~essfully used in intrathoracic 
applications (2, 8) to resolve the empyema 
associated with tuberculosis. 
TRYPSIN .AND ,ITS ACTIONS 
Trypsin is available to the veterinary 
profession in a purified, lyophilized crys-
talline form (9). This for;m (Tryptar-
Vet®, Armour Veterinary Laboratories) 
is the activated trypsin and is ready to 
function, when applied directly to moist 
wounds or applied by irrigatidns or wet 
packs to q.ry necrotic type lesiqns. It has 
been demonstrated both expe~imentally 
(2) and clinically (3,8) that the I£ollowing 
sequence of events occur when trypsin is 
applied to wounds. 
The necrotic material can be seen ito be-
come loosened and dissolved from the sub-
strate of the wound. Trypsin does not 
digest normal healthy tissue. Pathological 
leucocytes rapidly disappear from the 
wound and normal leucocytes enter into 
the area. Healthy regenerating tissue 
forms rapidly to accelerate healing. 
There is no side reaction whatsoever 
attendant with trypsin usage in open, 
freely-draining wounds. In treating car-
uncle conditions, as in fistulous withers of 
the llorse, adequate drainage must be es-
tablished. Tryptic digestion of tissue may 
liberate histamine substances (6, 8, 10) 
which could be absorbed and cause a 
transient pyrexia and occasional stinging. 
In these . instances antihistamine adminis-
tered at usual dosages for the species will 
counteract this effect. Upon repeated use 
of trypsin this phenomenon does not ap-
pear again. 
The digestive action of trypsin breaks 
down proteins and partially hydr;olyzed 
proteins at peptide linkages (1, 11). This 
results in liquefaction of necrotic tissue 
without formation of ~ntermediate pro-
ducts which may cause anaphylactic reac-
tions. In the human and. the animal, tryp-
sin does not cause production of antibodies 
or any undesirable side reactions when' 
applied topically or in body cavities where 
aspiration may be accomplished or free 
drainage established. -
It has been demonstrated clinically (3, 
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6, 7) and most recently in experimental 
animals that severely infected wounds or 
cleanly induced surgical wounds (12) 
treated with trypsin heal more rapidly 
than similar wounds in control animals.' 
Surgical excision of the nerves controlling 
the blink reflex of rabbits resulted in re-
generation of the nerves on an average of 
5 days earlier with trypsin treated animals 
as opposed to controls. W oundhealing 
which occurs at the skin surface heals on 
an average of 2 days earlier than controls. 
Puncture wounds on test animals heal 
much more rapidly the first 3 days follow-
ing injury in trypsin treated cases than do 
untreated controls or controls treated with 
hydrocortisone. 
Trypsin injected parenterally (2, 13, 14, 
15) re,sults in a pronounced anti-inflam-
matory response being elicited in a variety 
of pathological conditions where inflam-
mation is always present. However, it has 
been found that intravenous use of trypsin 
interferes with the anti-clotting mechan-
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isms in the blood stream and such action 
may result in formation of intravascular 
clots (16,17). This phenomenon will occur 
in laboratory animals even in the absence 
of calcium ions. In many case studies (2, 
3, 6, 7, 8) trypsin has resulted in the cir-
cumvention of radical surgery 'and has 
effected permanent healing of many 
chronic conditions which were refractive 
to the accepted means of therapy. 
This has been adequately demonstrated 
by Johnson, et al., in the following com-
mon conditions. For fistulous withers in 
horses (cases in which drainage has been 
established naturally or where surgical 
. incision was required) approximately 
400,000 units (Armour units, 1,000 units 
= 1 mg. tryptic activity) 'Of t:rypsin daily 
for 7 days has induced normal repair 
prosesses. 
A solution of the enzyme may be inject-
ed into the area- or irrigated through the 
fistulous tracts .. 'J:'he crystalline material 
may be blowrtinto the lesions with a pow-
der blower, or it may be inserted in fistu-
lous tracts by use of gelatin capsules. 
Foot rot in cattle as with foot canker in 
horses has been satisfactorily resolved 
through daily use of trypsin. Two-hundred 
thousand to 400,000 units applied directly 
to the lesion or injected into the fistula is 
sufficient for a daily treatment. Continued 
for a week or less, this therapy results in 
normal healing of the condition. This has 
in several instances circumvented ampu-
tation of the claw to correct foot rot. 
Trypsin may be injected directly into 
pus-filled joint capsules, allowed to work 
for a few hours, then aspirated, leaving the 
joint free of caseous or purulent material. 
In cases of gangrenous and purulent 
mastitis, depending upon the size of the 
infected area, 200,000 to 800,000 units of 
trypsin· daily results in considerable re-
duction- of inflammation. The trypsin so-
lution may be introduced into the affected 
quarter either by way of the teat canal or, 
if this is impossible, injected with a hypo-
dermic needle directly into the affected 
area~ In the case of gangrenous mastitis, 
an incision in the area may bE;! required to 
~drain the liquefied material. This therapy 
must be carried out with indicated antibi-
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otics to cont:rol the infection. 
It has been found in human cases (8) 
that the introduction of 500,000 units into 
the thoracic cavity of chronic tubercular 
cases with empyema results in a rapid li-
quefaction of the empyema making pos-
sible easy aspiration and drainage of the 
. affected pleura. Also, after a few treat-
ments the tubercular organisms can no 
longer be detected in the affected area. 
Similar effects upon bacteria (2, 3) are 
noted in many other infected type wounds. 
Following a few applications of trypsin 
the invading bacteria carinot be detected. 
This is assumed to be due to the effect of 
trypsin upon altering the substrate of the 
area of injury so that pathogenic bacteria 
can no longer secure nutrition from the 
site and, hence, die away. It has also been 
shown that trypsin digests the capsular 
material from many pathogenic micro-
organisms. This must not be construed to 
mean that trypsin is antibiotic, but this 
feature combined with such agents en-
hances the effect of antibiotic therapy in 
many conditions. . 
Chronically infected sinuses in cattle 
and horses have been cured through in-
troduction of trypsin solution into the si-
nus and allowing it to remain for about 
24 hours, then tilting the head or estab-
lishing surgical drainage to drain out the 
liquefied material. This resulted under 
conditions where antibiotics or methods of 
flushing the sinus hadyield~d poor results. 
In t:reatmentt of topical \:wounds, ab-
scesses and hematomas, the, amount' of 
trypsin to use depends upon \ the extent~ 
and nature of the injury. On \he whole, 
small lesions, a few inches in area, would 
not require more than 50,000 tq 100,000 
units of trypsin daily until resolution of 
the condition is evident. Most of these 
resolve after one to three applications of 
t:rypsin. On more extensive areas,· as one 
might encoUnter in burns or where much 
loss of. tissue has occured with acute in-
fection and necrosis, several million units 
inaybe required to complete the course 
of treatment. 
Effective dosage will come with experi-
ence and usage of the product. As has been 
indicated previously, one can observe 
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(over a 30-minute period of time) the ra-
pid digestive action of trypsin upon ne-
crotic tissue. This may serve as an index 
for future cases and provide a guide for 
the duration of treatment necessary. 
Trypsin must be considered as an ad-
junct in treatment of dirty, infected and 
necrotic wounds. Surgical debridement 
could result in greater loss of body sub-
stance and perhaps failure to remove some 
of the foci of necrosis which may be deep-
er than is possible to reach. It is easy to see 
that removal of causes which impede heal-
ing and which can be accomplished by 
enzymatic debridement is often to be 
preferred to more radical approaches. 
CHYMOTRYPSIN 
Chymotrypsin, an analogue of trypsin, 
is commercially produced from beef pan-
creas glands. Its local action upon protein 
tissue is similar to that of trypsin (1, 18). 
Chymotrypsin as a purified crystalline 
material will soon be available to veterin-
arians for small animal use (Kymar®, Ar-
mour Veterinary Laboratories' oil sus-
pension of pure crystalline chymotrypsin). 
However, the use of this material in hu-
man and veterinary medicine is not for 
topical application. 
Chymotrypsin may be safely injected 
parenterally (intramuscularly) in oil or 
aqueous suspensions. It does not interfere 
with the clotting mechanisms of the blood 
and possesses remarkable anti-inflamma-
tory actions (2, 15, 18, 19, 20, 21). As op-
posed to many anti-inflammatory products 
on the market, this enzyme does not have 
any effect upon the endocrine system of 
the body. Its mode of action is at present 
unproved. It does appear to have a selec-
tive activity which takes place at sites of 
inflammation and reduces the edema, pain, 
and swelling, regardless of cause. 
The products may be used prophylactic-
ally in preventing inflammatory condi-
tions. This has been effective in preventing 
inflammation which follows surgical oper-
ations such as intestinal surgery, eye sur-
gery, fracture repair, etc. Given prior to 
such surgical procedures, the edema is 
held down and rapid healing allowed to 
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take place. At present this product does 
not appear to be as effective as other anti-
inflammatory agents for skin conditions. 
Gillispie (22), reporting upon 141 cases 
of all types in small animals, found that, as 
an anti-inflammatory agent, chymotrypsin 
was of definite benefit in as many as 75 to 
85 per cent of the common conditions for 
which it was used. The application of the 
product to the running horse (2) has re-
sulted in dramatic effects upon rate of 
healing and resolves trauma-induced in-
juries in a much more rapid period of 
time than had previously been experi-
enced. 
The enzyme may be used prophylactic-
ally as well as therapeutically in all con-
ditions in which inflammation and edema 
retard healing or present a danger to the 
involved organ. The dosage range which 
has been employed in small animals is as 
follows: cats and dogs up to 10 lbs., % cc. 
intramuscularly every 12 hours; dogs 10 
to 50 Ibs., 1f2 cc. every 12 hours; dogs over 
50 Ibs., % to 1 cc. every 12 hours. In case 
of severe inflammatory reaction, as in 
massive trauma, these doses may be given 
every 8 hours to effect. In large animals 
doses of 3 to 5 cc. daily result in similar 
effects. 
Some specific conditions in which chy-
motrypsin is effective in controlling the 
inflammatory processes and the resultant 
pain are as follows: 
1. Accident or non-surgical trauma as 
bone fractures, lacerations, contusions. 
2. Surgical trauma as mammary tumor 
excision, perineal hernia correction, open 
reduction of bone fractures, abdominal 
surgery. 
3. Inflammation of the eye and eyelids 
as iritis, iridocyclitis, keratitis, conjunc-
tivitis, post-operative panophthalmitis. 
4. Myositis. 
5. Cellulitis. 
6. Abscesses. 
Chymotrypsin hastens the absorption of 
hematomas, post-operative blood clots in 
the anterior chamber of the eye and hy-
popyon. 
By reducing inflammation and edema, 
circulation is restored which in turn 
hastens absorption and halts tissue necro-
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sis with an end result of enhanced healing 
with a minimum of pain. 
The enzyme is non-toxic and has no un-
toward side effects. It may be used simul-
taneously with other therapeutic agents 
without interference. 
SUMMARY 
Purified crystalline trypsin is being 
widely used in medicine and in veterinary 
medicine as a substitute for the scalpel in 
debriding wounds and for the liquefaction 
of caseous and purulent exudates in ab-
scesses and in body cavities. The enzyme is 
safe in topical usage and has only occa-
sional mild side effects if excessively used 
in body cavities. 
Trypsin accomplishes effective debride-
ment of wounds and avoids the possibility 
of greater loss of substance and possible 
injury to underlying structures which may 
result from surgical debridement mea-
sures. It may also be used in conjunction 
with surgical procedures to enhance heal-
ing in certain difficult cases. 
Chymotrypsin, a new enzyme anti-in-
flammatory agent, ,is soon to be available 
to the veterinary profession. It is fully as 
effective as adrenal steriod type hormones 
in treating most comparable inflammatory 
conditions. It possesses the outstanding 
feature of being absolutely safe from any 
side reactions in the patient and does not 
endanger the function or structures of the 
endocrine system. 
Both enzymes are economical to use in 
routine practice procedures. They are ex-
cellent forward steps in relieving the prac-
titioner from more crude or hazardous 
methods of treating applicable conditions 
in pets and domestic livestock. 
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